1606 Corp. signs non-binding LOI to acquire strategic stake in AI biotech Adnexus

1606 CORP.

LOI for a strategic stake in Adnexus, an AI biotech focused on early drug discovery and infectious disease research.
Adnexus develops fully human monoclonal antibodies using immune B-cells from recovered HIV and SARS-COV-2 patients.
Transaction subject to customary due diligence and conditions; no deal value or stake percentage disclosed.
CEO Austen Lambrecht states the partnership aligns with expanding AI capabilities in healthcare.
1606 Corp. (OTC Pink: CBDW) will present at the 150th NIBA Show in Fort Lauderdale on August 5, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.